Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review

Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review

Jin Wang,1– 3,* Dongying Liao,1– 3,* Xuemin Zhang,1– 3 Changhong Miao,1– 3 Kuang Chen1– 3 1Department of Emergency, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, People’s Republic of China; 2National Clinical Research Center for Chine...

Full description

Bibliographic Details
Main Authors: Wang J, Liao D, Zhang X, Miao C, Chen K
Format: Article
Language:English
Published: Dove Medical Press 2023-04-01
Series:Breast Cancer: Targets and Therapy
Subjects:
her2-low breast cancer
monoclonal antibodies
antibody–drug conjugates
trastuzumab deruxtecan
immunotherapy
Online Access:https://www.dovepress.com/can-patients-with-her2-low-breast-cancer-benefit-from-anti-her2-therap-peer-reviewed-fulltext-article-BCTT

Internet

https://www.dovepress.com/can-patients-with-her2-low-breast-cancer-benefit-from-anti-her2-therap-peer-reviewed-fulltext-article-BCTT

Similar Items